Molecular Templates Future Growth
Future criteria checks 0/6
Molecular Templates's revenue and earnings are forecast to decline at 118.3% and 50.6% per annum respectively while EPS is expected to grow by 12.2% per annum.
Key information
-50.6%
Earnings growth rate
12.2%
EPS growth rate
| Biotechs earnings growth | 30.4% |
| Revenue growth rate | -118.3% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 15 Aug 2024 |
Recent future growth updates
Recent updates
Earnings Release: Here's Why Analysts Cut Their Molecular Templates, Inc. (NASDAQ:MTEM) Price Target To US$18.00
Aug 17
Molecular Templates, Inc.'s (NASDAQ:MTEM) Shares Bounce 27% But Its Business Still Trails The Industry
Jul 30Little Excitement Around Molecular Templates, Inc.'s (NASDAQ:MTEM) Revenues As Shares Take 48% Pounding
Apr 03Lacklustre Performance Is Driving Molecular Templates, Inc.'s (NASDAQ:MTEM) 26% Price Drop
Dec 20There's No Escaping Molecular Templates, Inc.'s (NASDAQ:MTEM) Muted Revenues Despite A 45% Share Price Rise
Apr 17What Does The Future Hold For Molecular Templates, Inc. (NASDAQ:MTEM)? These Analysts Have Been Cutting Their Estimates
Nov 16Time To Worry? Analysts Are Downgrading Their Molecular Templates, Inc. (NASDAQ:MTEM) Outlook
Aug 14Molecular Templates GAAP EPS of -$0.44 misses by $0.01, revenue of $4.42M misses by $2.6M
Aug 11Rock star Growth Puts Molecular Templates (NASDAQ:MTEM) In A Position To Use Debt
Apr 29Health Check: How Prudently Does Molecular Templates (NASDAQ:MTEM) Use Debt?
Dec 30Some Analysts Just Cut Their Molecular Templates, Inc. (NASDAQ:MTEM) Estimates
Nov 25Is Molecular Templates (NASDAQ:MTEM) Using Debt In A Risky Way?
Sep 22News Flash: Analysts Just Made A Notable Upgrade To Their Molecular Templates, Inc. (NASDAQ:MTEM) Forecasts
Aug 15Need To Know: Analysts Just Made A Substantial Cut To Their Molecular Templates, Inc. (NASDAQ:MTEM) Estimates
May 18Brokers Are Upgrading Their Views On Molecular Templates, Inc. (NASDAQ:MTEM) With These New Forecasts
Mar 21Need To Know: The Consensus Just Cut Its Molecular Templates, Inc. (NASDAQ:MTEM) Estimates For 2021
Feb 21Is Molecular Templates (NASDAQ:MTEM) A Risky Investment?
Jan 26
Molecular Templates updates on study of MT5111, plans breast cancer expansion cohort in 1H21
Dec 22Here's What We Think About Molecular Templates' (NASDAQ:MTEM) CEO Pay
Dec 04Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 1 | -33 | N/A | N/A | 1 |
| 12/31/2024 | 12 | -21 | N/A | N/A | 1 |
| 6/30/2024 | 25 | -16 | -24 | -24 | N/A |
| 3/31/2024 | 32 | -18 | -28 | -28 | N/A |
| 12/31/2023 | 57 | -8 | -42 | -42 | N/A |
| 9/30/2023 | 53 | -26 | -55 | -55 | N/A |
| 6/30/2023 | 50 | -47 | -73 | -72 | N/A |
| 3/31/2023 | 48 | -60 | -84 | -81 | N/A |
| 12/31/2022 | 20 | -93 | -92 | -89 | N/A |
| 9/30/2022 | 35 | -81 | -97 | -93 | N/A |
| 6/30/2022 | 33 | -87 | -98 | -93 | N/A |
| 3/31/2022 | 44 | -78 | -104 | -100 | N/A |
| 12/31/2021 | 39 | -83 | -34 | -30 | N/A |
| 9/30/2021 | 24 | -101 | -35 | -29 | N/A |
| 6/30/2021 | 26 | -94 | -30 | -24 | N/A |
| 3/31/2021 | 18 | -110 | -30 | -23 | N/A |
| 12/31/2020 | 19 | -105 | -91 | -84 | N/A |
| 9/30/2020 | 22 | -92 | -56 | -48 | N/A |
| 6/30/2020 | 21 | -107 | -57 | -45 | N/A |
| 3/31/2020 | 19 | -85 | -42 | -32 | N/A |
| 12/31/2019 | 22 | -69 | -35 | -25 | N/A |
| 9/30/2019 | 21 | -60 | -27 | -20 | N/A |
| 6/30/2019 | 24 | -27 | -16 | -13 | N/A |
| 3/31/2019 | 20 | -28 | -11 | -6 | N/A |
| 12/31/2018 | 13 | -30 | -10 | -4 | N/A |
| 9/30/2018 | 9 | -31 | -38 | -32 | N/A |
| 6/30/2018 | 3 | -36 | -32 | -26 | N/A |
| 3/31/2018 | 2 | -31 | N/A | -21 | N/A |
| 12/31/2017 | 3 | -24 | N/A | -14 | N/A |
| 9/30/2017 | 3 | -20 | N/A | -7 | N/A |
| 6/30/2017 | 2 | -13 | N/A | -6 | N/A |
| 3/31/2017 | 3 | -11 | N/A | -10 | N/A |
| 12/31/2016 | 2 | -13 | N/A | -9 | N/A |
| 12/31/2015 | 1 | -7 | N/A | -4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MTEM is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MTEM is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MTEM is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MTEM's revenue is expected to decline over the next 3 years (-118.3% per year).
High Growth Revenue: MTEM's revenue is forecast to decline over the next 3 years (-118.3% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MTEM's Return on Equity is forecast to be high in 3 years time